Skip to main content
Lubomir Sokol, MD, Hematology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

LubomirSokolMD

Hematology Tampa, FL

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

Overview of Dr. Sokol

Dr. Lubomir Sokol is a hematologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital, and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from University Karlovy, Lek Fak Ii and has been in practice 36 years. Dr. Sokol accepts several types of health insurance, listed below. He is one of 34 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 6 doctors at Tampa General Hospital who specialize in Hematology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2000 - 2002
  • LSU Health Sciences Center/University Hospital and Clinics (Lafayette)
    LSU Health Sciences Center/University Hospital and Clinics (Lafayette)Residency, Internal Medicine, 1997 - 1999
  • University Karlovy, Lek Fak Ii
    University Karlovy, Lek Fak IiClass of 1981

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2000 - 2026
  • LA State Medical License
    LA State Medical License 1999 - 2024
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
    Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer

Abstracts/Posters

  • Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...
    Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...
    Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R
    Lubomir Sokol, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

  • Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

  • Hospitalization Outcomes in Patients with CTCL: A Multi-Center Study
    Hospitalization Outcomes in Patients with CTCL: A Multi-Center StudyMarch 26th, 2022
  • Poster Awards Announced Ahead of 2022 Meeting in Boston
    Poster Awards Announced Ahead of 2022 Meeting in BostonMarch 7th, 2022
  • Potential New Drug Target to Treat Cutaneous T Cell Lymphoma
    Potential New Drug Target to Treat Cutaneous T Cell LymphomaDecember 21st, 2020

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    AvMed Health Open Access
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Florida - Employer Group PPO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment